1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

TEVJF
Teva Pharmaceutical Industries LimitedUS flagOther OTC
33.00
USD
- -
- -
38.43BMarket Cap
Teva Pharmaceutical Industries Limited
TEVJF
(Other OTC)

Recent

price

33.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
17.99
20.58
23.3
23.93
23.77
22.98
22.94
21.51
17.9
15.48
15.21
14.41
13.45
14.16
14.63
15.07
15.08
Revenue per Share
3.72
3.1
2.25
1.49
3.58
1.84
0.07
-16.26
-2.35
-0.92
-3.64
0.38
-2.2
-0.5
-1.45
1.23
1.36
Basic EPS, GAAP
3.82
3.46
3.98
2.6
4.92
5.58
3.13
1.33
1.76
0.2
0.58
0.21
0.94
0.75
0.66
1
1.02
Free Cash Flow per Basic Share
0.75
0.9
0.98
1.28
1.36
1.35
1.63
1.14
0.02
0.05
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.46
12.73
14.22
14.82
16.98
17.43
14.3
-3.69
-5.78
-6.32
-9.94
-9.5
-11.64
-12.04
-13.36
-11.97
-11.59
Book Value per Share
1.14
-7.04
-4.28
-3.32
-0.66
-0.07
-36.15
-30.45
-22.65
-19.26
-16.88
-14.76
-13.79
-12.9
-12.24
-10.36
-9.73
Tangible Book Value per Share
896
890
872
849
853
855
955
1,016
1,021
1,091
1,095
1,102
1,110
1,119
1,131
1,145
1,151
Basic Weighted Avg Shares
16,121
18,312
20,317
20,314
20,272
19,652
21,903
21,853
18,271
16,887
16,658
15,879
14,925
15,845
16,544
17,257
17,348
Sales/Revenue/Turnover
26.56
21.9
20.57
19.5
22.15
25.41
21.02
18.26
15.7
16.11
18.36
19.52
18.02
20.16
20.33
22.9
23.07
Operating Margin (%)
977
1,069
1,708
1,642
1,508
1,308
1,524
2,112
1,842
1,722
1,557
1,330
1,308
1,153
1,059
1,002
999
Depreciation Expense
3,331
2,759
1,963
1,269
3,055
1,588
329
-16,265
-2,150
-999
-3,990
417
-2,446
-559
-1,639
1,410
1,564
Net Income, GAAP
7.76
4.3
- -
- -
16.25
26.96
63.23
- -
- -
- -
- -
32.07
- -
- -
- -
- -
48.46
Effective Tax Rate (%)
20.66
15.07
9.66
6.25
15.07
8.08
1.5
-74.43
-11.77
-5.92
-23.95
2.63
-16.39
-3.53
-9.91
8.17
9.02
Profit Margin (%)
2,348
777
3,467
1,755
2,107
5,393
-1,260
-2,539
-528
-210
-159
1,546
582
238
-244
490
178
Working Capital
4,110
10,236
11,712
10,387
8,566
8,358
32,524
28,829
26,700
24,997
23,210
22,033
19,452
18,481
16,298
15,274
14,295
LT Debt
22,002
22,343
22,867
22,636
23,355
29,927
34,993
18,745
15,794
15,063
11,061
11,244
8,598
8,126
5,720
7,914
8,232
Total Equity
14.69
11.68
- -
- -
10.98
9.92
3.06
- -
- -
- -
- -
5.85
- -
- -
- -
- -
- -
Return on Invested Capital (%)
24.48
14.06
- -
- -
13.36
6.68
1.32
- -
- -
- -
- -
6.45
- -
- -
- -
- -
108.23
Return on Capital (%)
41.42
26.65
16.54
10.16
22.57
10.7
0.48
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
24
1,820
2,612
LT Borrowings
16,766
14,986
14,015
LT Finance Leases
283
288
280
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,147
1,150
1,164
Market Capitalization
22,938
32,949
32,633

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
12,736
13,946
13,710
Cash, Cash Equivalents & STI
2,203
3,556
3,741
Accounts Receivable, Net
3,810
3,709
3,393
Inventories
3,323
3,179
3,176
Total Current Liabilities
11,491
13,456
13,532
Payables & Accruals
5,344
5,218
5,212
ST Debt
24
1,820
2,612
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.51%
-3.72%
38.36%
Free Cash Flow
34.08%
60.31%
53.27%
Net Income, GAAP
-583.1%
-173.4%
-186.03%
Sales/Revenue/Turnover
-0.99%
0.84%
4.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,819
4,164
4,332
4,229
16,544
2025
3,891
4,176
4,480
4,711
17,257
2026
3,981
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.75
-0.39
-0.19
-1.45
2025
0.18
0.25
- -
0.42
1.23
2026
0.32
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Endo International plc (ENDP)
SNDL Inc. (SNDL)
Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ)
The United Laboratories International Holdings Limited (3933.HK)
Business
Teva Pharmaceutical Industries Limited develops, manufactures, markets and distributes generic medicines, innovative branded drugs, biopharmaceuticals, over-the-counter products and active pharmaceutical ingredients worldwide. The company offers a broad portfolio of generic medicines in dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams; sterile products, hormones, high-potency drugs and cytotoxic substances in parenteral and solid forms; and generic products with medical devices and combination therapies; alongside innovative products such as AUSTEDO for chorea associated with Huntington's disease and tardive dyskinesia, AJOVY for migraine prevention, UZEDY for schizophrenia, COPAXONE for relapsing multiple sclerosis, BENDEKA and TREANDA for certain lymphomas, ProAir RespiClick and QVAR RediHaler for asthma, and biosimilars including SELARSDI; plus respiratory inhalers like DuoResp Spiromax and AirDuo RespiClick, and APIs sold to third parties through affiliate Teva Active Pharmaceutical Ingredients. Teva operates through three main segments--North America, Europe and International Markets--with manufacturing facilities in Israel, North America, Europe, Australia and South America, targeting healthcare providers, pharmacies and patients across therapeutic areas including central nervous system disorders, oncology, respiratory diseases, cardiovascular conditions and infectious diseases. Founded in 1901 with roots in Jerusalem through predecessor Salomon, Levin and Elstein Ltd. and formally established in 1935, Teva is headquartered in Petah Tikva, Israel. In recent developments, Teva accelerates its Pivot to Growth strategy launched in 2025 with targets for a greater than $5 billion innovative medicines franchise by 2030 driven by AUSTEDO, AJOVY and UZEDY plus pipeline assets like olanzapine LAI, duvakitug and emrusolmin; reaffirms 2027 goals of 30% operating margins, over $2.7 billion free cash flow and 2x net leverage; enters a June 2025 strategic partnership with Fosun Pharma for anti-PD1-IL2 therapy TEV-56278 in oncology; launches first-to-market generics including Sandostatin LAR Depot and liraglutide (authorized generic of Victoza) in 2024-2025; and expands its biosimilars pipeline to 18 assets with SELARSDI U.S. launch in early 2025.